Just when the world seemed to settle into a post-pandemic rhythm, a new COVID-19 variant—NB.1.8.1, nicknamed Nimbus—is gaining ground and rattling global health authorities. With its hallmark symptom being an agonizing sore throat that patients describe as feeling like “swallowing razor blades,” the variant has already led to a noticeable rise in infections across several countries.

First identified in early 2025, this Omicron subvariant is making headlines as cases spike across Asia and begin to surface in North America, Europe, and Australia as well. With international mobility returning to pre-pandemic levels, global health experts are closely monitoring its trajectory.

NB.1.8.1 is a mutated form of the Omicron variant, it is continuing the trend of subvariants that are more transmissible but, so far, not necessarily more severe. It was first detected and quickly spread through densely populated regions of China and Hong Kong.

By late April, the World Health Organization (WHO) reported that NB.1.8.1 accounted for approximately 10.7% of globally submitted genomic sequences—up from just 2.5% a month earlier. This rapid expansion prompted the WHO to designate it as a “variant under monitoring” on May 23.

What Makes NB.1.8.1 Different?

What sets NB.1.8.1 or Nimbus, apart from earlier COVID-19 variants is its unique set of symptoms, most notably the intense sore throat.

Patients across various countries, including Thailand, Indonesia, and the UK, have described a "razor blade" sensation in the throat, far more painful than the sore throats associated with previous variants.

Virologists, including Australia’s Dr. Lara Herrero of Griffith University, believe this new variant has a higher transmission potential and increased immune evasion capabilities, meaning it can more easily bypass natural or vaccine-induced immunity, contributing to its rapid spread.

Key Symptoms of New COVID Variant NB.1.8.1 To What to Watch For

While the classic COVID symptoms like fever and fatigue remain present, NB.1.8.1 adds a painful twist to the mix. Here’s what patients have been reporting:

• Severe sore throat described as 'swallowing razor blades'
• Fatigue and body aches
• Mild to moderate fever
• Congestion and runny nose
• Persistent mild cough
• Gastrointestinal issues such as diarrhea and nausea in some cases

Healthcare professionals caution that these symptoms can be confused with the flu or seasonal allergies, making early detection more challenging without testing.

How Dangerous Is New COVID Variant NB.1.8.1?

Despite its painful symptoms and swift spread, current data suggests that NB.1.8.1 is not more deadly than prior variants. The WHO has emphasized that existing COVID-19 vaccines remain effective at preventing severe disease and hospitalization caused by this strain.

A pre-print study (still pending peer review) also indicates that although the variant demonstrates high immune evasion, the severity of illness appears consistent with previous Omicron variants. That said, under-testing in many parts of the world means the actual scale of spread may be underreported.

Several factors contribute to the rise in COVID cases globally:

Reduced testing and complacency: Fewer people are getting tested for COVID-19 compared to the height of the pandemic, making tracking more difficult.

Seasonal mobility: Increased travel and fewer restrictions may be aiding the variant’s spread.

Vaccine fatigue and rollback of mandates: Recent policy changes, such as the rollback of vaccine recommendations for children and pregnant women in the U.S., could affect future immunization rates.

Dr. Robert F. Kennedy Jr., Health and Human Services Secretary under the Trump administration, recently stated a controversial shift in vaccine recommendations, despite evidence supporting vaccination—especially for pregnant women—to protect both mother and baby.

How To Stay Safe and Protected?

Health experts explain that COVID-19 vaccines continue to be a first and most important aspect of defense and protection, including against NB.1.8.1. There is no current evidence that the variant undermines vaccine effectiveness against severe illness.

The American College of Obstetricians and Gynecologists (ACOG) also urges pregnant women to stay up to date on their COVID vaccinations, citing strong data showing that vaccinated mothers pass antibodies to their newborns, offering early protection.

While NB.1.8.1 isn’t considered a “variant of concern” yet, its rapid rise in numbers and severe sore throat symptoms have placed it on the global radar. The good news is that existing public health measures—vaccination, hygiene, mask-wearing in high-risk settings—still work.

Individuals who experience persistent throat pain, especially if accompanied by other flu-like symptoms, are advised to get tested and isolate as necessary.

The present guidance from public health officials mirrors what the international community has collectively embraced as received wisdom:

• Keep practicing proper hand hygiene.
• Use masks in indoor, poorly ventilated, or congested settings.
• Self-isolate and get tested if having cold-like symptoms.
• Stay home and refrain from unnecessary social contacts if ill.

The emergence of NB.1.8.1 is a sharp reminder that COVID-19 is far from over. While it may no longer dominate headlines like it did during the global crisis, its ability to mutate and spread remains potent.

If your sore throat feels unusually painful—like swallowing glass or razor blades, it might be time to test, mask up, and protect those around you.

Every year on June 14, World Blood Donor Day is observed. As per the World Health Organization (WHO), the world celebrates World Blood Donor Day, a global tribute to the millions of voluntary, unpaid blood donors who give others a second chance at life.

Each time you donate blood, you’re giving more than a life-saving gift—you’re enabling critical medical tests that guide treatment and improve care. This World Blood Donor Day, remember: your donation isn’t just for emergencies, it plays a vital role in everyday healthcare too.

History of World Blood Donor Day

The World Blood Donor day dates back to 2004, when it was established by the WHO and is partners. The aim for this was to create a global recognition for he contributions of voluntary donors and to encourage safe blood practices in every country.

Since then, it has become an essential health campaign that brings attention to the need for regular donation. The day also celebrates unsung heroes who, through this simple ac, save lives.

World Blood Donor Day 2025 Theme

This year, as notes WHO, the theme is "Give blood, give hope, together we save lives".

This year’s World Blood Donor Day campaign, with the slogan “Give blood, give hope: together we save lives,” emphasizes the life-changing role blood donors play in saving lives. It underscores the power of community and collective action, showcasing how a simple act of donating blood can create a ripple effect of hope for those in need. Through the sharing of personal stories from both recipients and donors, the campaign aims to inspire more individuals, particularly young adults, to take part in blood donation—whether as first-time donors or as regular contributors.

The campaign will feature, as WHO notes, a variety of activities to celebrate and acknowledge the efforts of blood donors. These could include commemorative events, workshops, social media initiatives, donor appreciation ceremonies, and special broadcasts to honor those who give blood. In addition, musical and artistic performances may be held to express gratitude, while impactful stories will be shared to raise awareness about the importance of blood donation. This year’s objectives are to increase public awareness about the critical need for blood donations, encourage both new and returning donors to donate regularly, and promote solidarity and compassion through these life-saving acts. Furthermore, the campaign seeks to rally support from governments and global partners to ensure sustainable national blood programs, aiming for universal access to safe blood transfusion worldwide.

World Blood Donor Day Significance

This day encourages more and more people to donate blood and save a life. Blood transfusions provide life-saving support, notes WHO. This is especially true for women who experience bleeding related to pregnancy and childbirth, or children who suffer from severe anemia due to malaria or malnutrition.

Other scenarios, notes WHO, where blood transfusion helps include, complex medical procedures, patients with sickle-cell disease, thalassemia, hemophilia, or immune deficiency disorder, or for emergency responses, in cases of natural disasters or armed conflicts.

The England National Health Service (NHS) is the world's first healthcare system to offer a revolutionary blood cancer treatment called a "Trojan horse" drug. The trailblazing treatment, officially known as belantamab mafodotin, has the potential to add years to the lives of thousands of patients fighting multiple myeloma, a vicious and currently untreatable form of bone marrow cancer.

This innovation, now being rolled out to eligible patients throughout England, highlights the revolutionary promise of precision medicine and targeted treatments to change cancer care.

How Does This Therapy Work?

At the center of this medical innovation is belantamab mafodotin, also known as Blenrep and produced by GlaxoSmithKline. In contrast to traditional chemotherapy that gets into both healthy and cancer cells, this new medication uses a targeted approach: it binds to myeloma cells, enters them quietly, and delivers a fatal dose of chemotherapy directly within, effectively killing the malignancy from the inside out.

This "Trojan horse" metaphor comes from Greek mythology, as Greek warriors entered the city of Troy disguised within a wooden horse. In the same way, this drug corrupts cancer cells by smuggling a toxic payload into them disguised as an antibody—spared most healthy tissues in the process.

NHS England National Clinical Director for Cancer Professor Peter Johnson called the treatment "life-changing" and said, "Myeloma is an aggressive blood cancer, but the advent of belantamab mafodotin brings with it a new hope of highly extended disease control.

Multiple myeloma is a plasma cancer that arises in plasma cells present in the bone marrow. Although there are continued advances in medicine, the disease is still incurable and relapsing in nature. The majority of patients have a pattern of recurrence after remission, requiring multiple treatment lines.

Trials of belantamab mafodotin, particularly in combination with other drugs such as bortezomib and dexamethasone, have shown that the treatment can stop disease from progressing for a period of three years—three years longer than the 13-month postponement achieved with the drug of choice at present, daratumumab.

The National Institute for Health and Care Excellence (NICE), having checked the effectiveness and value for money, accelerated approval for the rollout of the treatment. NICE director Helen Knight stated, "This recommendation shows our determination to get patients the best treatment quickly while protecting value for the taxpayer."

Who Will Benefit?

The NHS rollout will first address about 1,500 patients per year in England that have relapsed or are resistant to their existing treatments. These are often those with advanced myeloma who have run out of other standard treatments.

Significantly, this represents a move toward personalized, next-generation treatments being accessible through public healthcare facilities—an accomplishment welcomed by health activists and oncologists alike.

Shelagh McKinlay, Myeloma UK's Director of Research and Advocacy, hailed the announcement: "We have campaigned aggressively for the last year to get this drug approved. It will change the lives of thousands of myeloma patients."

Paul Silvester, who is 60 and from Sheffield, was diagnosed with multiple myeloma in 2023. When ordinary treatment and even a bone marrow transplant did not halt the disease, he was put on an early-access trial for belantamab mafodotin at the Royal Hallamshire Hospital.

The change was almost instant," he explained. "In the first two or three weeks following the first dose, I was in remission. I like to think this treatment has brought the party balloons into the house."

Paul is now in remission and mapping out history-themed travel excursions—something he never thought he'd ever be able to do a few months ago.

How Does Belantamab Mafodotin Work?

Belantamab mafodotin is an antibody-drug conjugate (ADC), a new class of cancer drugs. The drug's antibody component targets a protein (BCMA) on the outside of myeloma cells. After binding to the cancer cell, the complex is taken into the cell where it drops off a potent chemotherapy drug, essentially killing it from within.

This internal targeting results in much less collateral damage to normal cells—a major problem with standard chemotherapy—and decreases the overall treatment burden.

Side Effects and Safety Issues

Although thought to be less toxic than many standard therapies, belantamab mafodotin is not without adverse effects. Patients can have dry eyes, blurred vision, and occasionally more severe ocular toxicity due to the mechanism of action of the drug leaking into surrounding tissues after cell kill.

Clinical teams are trained to monitor and manage these effects, often adjusting dosage or incorporating supportive therapies to preserve patient safety.

Health Minister Karin Smyth emphasized the significance of this development: “This groundbreaking therapy puts the NHS at the forefront of cancer innovation. By harnessing cutting-edge ‘Trojan horse’ technology, we’re offering new hope to blood cancer patients across the country.”

In fact, the move by the NHS to be the first healthcare system in the world to introduce this treatment establishes a precedent for the incorporation of high-cost, high-impact biologic therapies into national care.

With its effective implementation in England, belantamab mafodotin could soon be used as a worldwide standard of care for relapsed or refractory multiple myeloma. As other nations observe outcomes and cost-effectiveness trends, it is possible that health systems globally will look into implementing this Trojan horse technique.

Researchers in oncology are also looking at similar antibody-drug conjugates for other types of cancer, including breast, lung, and ovarian cancers—implying that we are just beginning to see what this technology has to give.

Dr. David Geier, a controversial orthopedic surgeon and known vaccine skeptic, is attempting to revisit long-debunked claims linking vaccines to autism. Recently hired by Health Secretary Robert F. Kennedy Jr., Geier is now reviewing historical safety data to investigate whether government agencies concealed crucial information.

Accessing CDC's Vaccine Safety Database

Geier is reportedly seeking access to the U.S. Centers for Disease Control and Prevention’s (CDC) Vaccine Safety Datalink (VSD), a repository of vaccine safety records from millions of patients. The VSD is maintained by a dozen major healthcare systems, each controlling its own data. Full access has always been tightly controlled due to privacy and misuse concerns.

Geier previously accessed the database in 2004 and 2006. However, according to The Wall Street Journal, CDC officials revoked his access both times, alleging he had misrepresented his research intentions.

Despite this, Geier is once again pushing to analyze the data. It remains unclear if access has been granted. A spokesperson for the U.S. Department of Health and Human Services (HHS) stated that the department intends to take a “fresh look at all data including old data,” and emphasized that they would “follow the science—wherever it leads.”

Scientific Community Raises Concerns

The scientific and public health communities have expressed concern over Geier's involvement. “He has no record in the scientific community of doing valid work,” said Dr. Walter Orenstein, former director of the CDC’s immunization program.

Geier and his late father, geneticist Mark Geier, have long promoted the theory that vaccines cause autism—an idea widely discredited by the medical community. The pair also introduced a controversial treatment using hormone-blocking drugs, which resulted in the revocation of Mark Geier’s medical license and disciplinary actions against David Geier for practicing medicine without a license.

At a 2015 conference, Geier defended his position, claiming the scientific community dismisses their findings without proper consideration. “They think that [the vaccine's link to autism has] been completely debunked,” he said at the time.

Kennedy's Role and the Larger Context

Robert F. Kennedy Jr., a vocal critic of vaccine mandates, has clarified that Geier will not lead autism research. Instead, his focus will be on identifying any possibly overlooked or hidden data within the CDC’s database.

“There has been a lot of monkey business with the VSD,” Kennedy stated in a previous congressional appearance.

Kennedy, who once authored a now-retracted Rolling Stone article alleging a vaccine-autism cover-up, cited a 2000 CDC conference that explored preliminary data on thimerosal—a mercury-based preservative once used in vaccines. Though early findings prompted questions, later analysis confirmed no link between thimerosal and autism. Thimerosal was removed from most vaccines in 2001, and final results were published in 2003.

Exploring Autism Causes and Rising Rates

While Geier conducts his review, the U.S. Department of Health and Human Services is separately examining rising autism rates. The CDC now estimates that 1 in 31 eight-year-olds in the U.S. were diagnosed with autism in 2022. Experts attribute the increase to a combination of better diagnostic methods, genetic factors, and increased awareness.

The National Institutes of Health (NIH) also plans to fund research into other possible causes, such as environmental toxins and diet. Meanwhile, Children's Health Defense, a nonprofit formerly led by Kennedy, is hosting an online event this week centered on what it calls the “autism cover-up.”